Treatment of the antiphospholipid antibody syndrome.
Numerous questions exist regarding the proper management of patients with the antiphospholipid antibody syndrome (APS). Several recent, randomized-controlled trials have been conducted that attempt to answer the fundamental questions of whom to treat, how to treat, and for how long treatment should last. These studies suggest that APS should be categorized by disease manifestations, and these presentations may have different treatment algorithms. A better understanding of the immune mechanisms that govern thrombosis in this syndrome has led to a wide array of innovative treatment approaches that will require meticulous study.
Wu
Christopher
C
Center for Innovative Therapy, UCSD School of Medicine, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0943, USA.
Kalunian
Kenneth
K
D016736:Antiphospholipid Syndrome / Q000150:complications / Q000517:prevention & control / Q000628:therapy*; D002388:Catastrophic Illness / Q000628:therapy; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000628:therapy; D011379:Prognosis; D020521:Stroke / Q000209:etiology / Q000628:therapy; D013923:Thromboembolism / Q000209:etiology / Q000628:therapy; D020246:Venous Thrombosis / Q000209:etiology / Q000628:therapy